Acyclic Carbon Bonded Directly To Triazole Ring Nitrogen Is Multiple Bonded To An Additional Carbon Patents (Class 548/268.4)
-
Patent number: 8785481Abstract: The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.Type: GrantFiled: September 28, 2011Date of Patent: July 22, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Douglas C. Beshore, Vadim Dudkin, Robert M. Garbaccio, Adam W. Johnson, Scott D. Kuduk, Jason W. Skudlarek, Cheng Wang, Mark E. Fraley
-
Publication number: 20140155370Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).Type: ApplicationFiled: June 28, 2013Publication date: June 5, 2014Inventors: Sharon Shacham, Michael Kauffman, Vincent P. Sandanayaka, Sharon Shechter
-
Patent number: 8614217Abstract: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions wherein A represents a tetrazoyl group, Het represents a pyridyl group or a thiazolyl group and X represents various substituents.Type: GrantFiled: July 3, 2009Date of Patent: December 24, 2013Assignee: Bayer Cropscience AGInventors: Christian Beier, Jürgen Benting, David Bernier, Isabelle Christian, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Pierre Genix, Daniela Portz, Ulrike Wachendorff-Neumann
-
Patent number: 8513230Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).Type: GrantFiled: March 5, 2011Date of Patent: August 20, 2013Assignee: Karyopharm Therapeutics, Inc.Inventors: Sharon Shacham, Michael Kauffman, Vincent P. Sandanayaka, Sharon Shechter
-
Patent number: 8492388Abstract: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. wherein A represents a tetrazoyl group, Het represents a pyridyl group or a thiazolyl group and X represents various substituents.Type: GrantFiled: July 3, 2009Date of Patent: July 23, 2013Assignee: Bayer Cropscience AGInventors: Christian Beier, Jürgen Benting, David Bernier, Isabelle Christian, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Pierre Genix, Daniela Portz, Ulrike Wachendorff-Neumann
-
Patent number: 8158642Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: October 15, 2009Date of Patent: April 17, 2012Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Christopher Michael Semko, Ying-zi Xu, Frank Stappenbeck, Jenifer Lea Smith, Kassandra Inez Rossiter, Juri Y. Fukuda, Andrei W. Konradi
-
Publication number: 20110275607Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).Type: ApplicationFiled: March 5, 2011Publication date: November 10, 2011Applicant: KARYOPHARM THERAPEUTICS, INC.Inventors: Sharon Shacham, Michael Kauffman, Vincent P. Sandanayaka, Sharon Shechter
-
Publication number: 20110172095Abstract: The present invention relates to compounds of the formula I in which the variables have the meanings defined in the claims and in the description.Type: ApplicationFiled: September 3, 2009Publication date: July 14, 2011Applicant: BASF SEInventors: Jochen Dietz, Thomas Grote, Wassilios Grammenos, Bernd Mueller, Jan Klaas Lohmann, Jens Renner, Sarah Ulmschneider, Marianna Vrettou
-
Publication number: 20110172096Abstract: The present invention relates to compounds of the formula I in which the variables have the meanings given in the claims and in the description.Type: ApplicationFiled: September 3, 2009Publication date: July 14, 2011Applicant: BASF SEInventors: Sarah Ulmschneider, Jochen Dietz, Jens Renner, Thomas Grote, Wassilios Grammenos, Bernd Mueller, Jan Klaas Lohmann, Marianna Vrettou
-
Publication number: 20100292472Abstract: The present invention can provide a novel medicament that is safe, cheap and effective for prophylaxis or therapy of apicomplexan infections, such as malaria and toxoplasmosis by applying a plant growth regulator selected from the group consisting of gibberellin inhibitors, cytokinins and ethylene inhibitors to the prophylactic or therapeutic treatment of such apicomplexan infections.Type: ApplicationFiled: January 22, 2009Publication date: November 18, 2010Inventors: Tomoko Toyama, Kisaburo Nagamune, Toshihiro Horii, Kazuyuki Tanabe
-
Patent number: 7820663Abstract: The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of ?7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on ?7 nAChRs in a mammal by administering an effective amount of a compound of Formula I.Type: GrantFiled: June 15, 2006Date of Patent: October 26, 2010Assignee: The Regents of the University of CaliforniaInventors: Derk J. Hogenkamp, Timothy B. C. Johnstone, Kelvin W. Gee
-
Publication number: 20090137637Abstract: This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R1, Q, W1, W2, R2a, L1, and R3, the pharmaceutical composition, the method of treating, and the therapeutic combination are as defined in the specification.Type: ApplicationFiled: December 5, 2005Publication date: May 28, 2009Applicant: PFIZER INC.Inventors: Joe Nahra, Patrick Michael O'Brien
-
Publication number: 20070238765Abstract: The present invention provides a compound of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Y, Ar, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.Type: ApplicationFiled: April 11, 2007Publication date: October 11, 2007Inventors: Xiao-Fa Lin, David Garrett Loughhead, Jason Manka, Counde O'Yang, Michael Soth, Dennis M. Yasuda
-
Publication number: 20040254373Abstract: The invention provides compounds of Formula I: 1Type: ApplicationFiled: June 30, 2004Publication date: December 16, 2004Applicant: Pfizer IncInventors: David W. Piotrowski, Bruce N. Rogers, William W. McWhorter, Daniel Patrick Walker, Jeffrey W. Corbett, Vincent E. Groppi, Daniel G. Rudmann
-
Publication number: 20030216571Abstract: The present invention is to provide novel tricyclic compounds having leukotriene antagonistic action and represented by the formula: 1Type: ApplicationFiled: July 31, 2002Publication date: November 20, 2003Inventors: Yoshiaki Kuroki, Hitoshi Ueno, Tetsushi Katsube, Tetsuo Kawaguchi, Eiji Okanari, Takashi Ikuta
-
Publication number: 20030125368Abstract: The present invention relates to compounds of the formula 1Type: ApplicationFiled: July 2, 2002Publication date: July 3, 2003Inventors: Subas M. Sakya, Andrei Shavnya, Bryson Rast
-
Publication number: 20030105105Abstract: The present application describes disubstituted pyrazolines and triazolines of formulae I and II: 1Type: ApplicationFiled: June 26, 2002Publication date: June 5, 2003Inventor: Donald J.P. Pinto